Intrathecal Rituximab in Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2019-09-02
Target enrollment:
Participant gender:
Summary
The goal of investigators is to study the kinetics of action of a single dose of
intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets in
progressive MS patients. Various markers of central nervous system inflammation (osteopontin,
Tumor Necrosis Factor α, IgG secretion) and neurodegeneration (neurofilament) are studied at
multiple time-points, assuming that a definitive action upon CSF biological targets would be
strongly predictive of a delayed clinical action.